1. Рекомендации по лечению артериальной гипертонии Европейского общества гипертонии и европейского общества кардиологов 2007 г.
2. Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients – focus on trandolapril/verapamil combination. Vasc Health Risk Manag 2007; 3 (4): 453–65. 
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805–16. 
4. Ostergren J, Poulter NR, Sever PS et al.; ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008; 26 (11): 2103–11.
5. Bangalore S, Messerli FH, Cohen JD et al.; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008; 156 (2): 241–7. 
6. Маколкин В.И. Комбинированная терапия артериальной гипертонии: фокус на сочетание антагониста кальция и ингибитора ангиотензин-превращающего фермента. www.medi.ru
7. Арутюнов Г.П. Гипотензивная терапия у курящих пациентов: выбор кардиолога. www.health-ua.com
8. Арутюнов Г.П., Кобалава Ж.Д., Карпов Ю.А. и др. Двойное открытое параллельное исследование по изучению влияния Квинаприла в сравнении с Лизиноприлом на дисфункцию эндотелия у курящих пациентов, страдающих мягкой и умеренной артериальной гипертензией в сочетании со стенокардией и имеющих микроальбуминурию. Сердце. 2007; 6 (4). 
9. Butler R, Morris AD, Struthers AD. Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci (Lond) 2001; 101 (1): 53–8.
10. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19 (Suppl. G): G48–53. 
11. www.euro.who.int/obesity
12. Haftenberger M et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutrition 2002; 5: 1147–62.
13. Kim MH. Prevalence of the Metabolic Syndrome and its Association with Cardiovascular Diseases in Korea. J Korean Med Sci 2004; 19: 195–201.
14. Bakris G, Molitch M, Hewkin A et al.; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29 (12): 2592–7.
15. Widimsky J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother 2000; 1 (3): 515–35. 
16. Ruggenenti P, Fassi A, Parvanova-Ilieva A et al. for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes. NEJM 2004; 351 (19): 1941–51.
17. Nakou E, Filippatos TD, Liberopoulos EN et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008; 9 (10):1629–39.
18. Widimsky J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother 2000; 1 (3): 515–35. 
19. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9 (2–3): 140–5.
20. Rubio-Guerra AF, Lozano-Nuevo JJ, Vargas-Ayala G et al. Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens 2006; 28 (7): 619–24.

О.М.Драпкина, Ю.В.Дуболазова 

Кафедра пропедевтики внутренних болезней Первого МГМУ им. И.М.Сеченова